Video Experimental Relacionado
Updated: May 1, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
10.3K
Experiencia inicial en el mundo real con los patrones de prescripción de lecanemab en Japón: El estudio LIFE
Kengo Kawaguchi1,2, Megumi Maeda1, Futoshi Oda1
1Department of Health Care Administration and Management Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Alzheimer's & dementia (Amsterdam, Netherlands)
|February 25, 2026
Resumen
Este estudio examinó el uso temprano de lecanemab en Japón, encontrando que se prescribió a mujeres mayores con deterioro leve. Las tasas de interrupción temprana fueron bajas, lo que sugiere una adopción cautelosa de este anticuerpo anti-amiloide-beta.
Área de la Ciencia:
- Neurología
- Farmacología
- Evidencia del mundo real
Sus antecedentes:
- Lecanemab, un anticuerpo anti-amiloide-beta, está aprobado a nivel mundial.
- Los datos demográficos y de uso en el mundo real de lecanemab son limitados fuera de los EE. UU.
- Comprender los patrones de adopción temprana es crucial para las estrategias de tratamiento.
Objetivo del estudio:
- Examinar el uso temprano en el mundo real de lecanemab en Japón.
- Determinar la tasa de interrupción de lecanemab en una cohorte japonesa.
- Identificar las características del paciente asociadas con la prescripción e interrupción de lecanemab.
Principales métodos:
- Análisis de datos de reclamaciones de 18 municipios japoneses (diciembre de 2023 - septiembre de 2024).
- Identificación de los pacientes que recibieron lecanemab y evaluación de la interrupción (brecha de prescripción ≥42 días).
- Evaluación de covariables que incluyen edad, sexo, puntuaciones cognitivas (MMSE, CDR) y comorbilidades.
Principales resultados:
- Se identificaron 123 pacientes que recibieron lecanemab; la mediana de edad fue de 76 años, 73,2% mujeres.
- La mayoría de los pacientes tenían deterioro cognitivo leve (MMSE ≥24: 60,9%; CDR 0,5: 79,3%).
- La tasa de interrupción fue de 1,04 por 100 personas-mes, y la mayoría ocurrió dentro de los 1,5 meses.
Conclusiones:
- Este es el primer informe sobre el uso de lecanemab en Asia, que involucra principalmente a mujeres mayores con deterioro cognitivo leve.
- Las bajas tasas de interrupción temprana sugieren una adopción cautelosa pero constante de lecanemab en Japón.
- Los hallazgos proporcionan información esencial sobre la aplicación en el mundo real de lecanemab en un nuevo contexto demográfico.
Más Videos Relacionados
Videos de Conceptos Relacionados
02:20Longitudinal Research
13.5K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.5K
01:16Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
283
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
283
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190
01:13Bioequivalence studies: Biowaivers
329
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
329